Empfehlungen zur Verhinderung berufsbedingter Exposition und Umweltexposition gegenüber zytotoxischen Medikamenten in der Veterinärmedizin^[*]

 

^* Deutsche Übersetzung der “Guidelines for preventing occupational and environmental exposure to cytotoxic drugs in veterinary medicine” des European College of Veterinary Internal Medicine of Companion Animals (ECVIM-CA),

• Literatur

• 1 Anwar WA, Salama SI, Serafy MM, Hermida S, Hafez AS. Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis 1994; 09: 315-317.
• 2 Ensslin AS, Huber R, Pethran A, Pethran A, Rommelt SchelerlH, Kulka U, Fruhmann G. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997; 70: 205-208.
• 3 Ensslin AS, Pethran A, Schierl R, Fruhmann G. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health 1994; 65: 339-342.
• 4 Ensslin AS, Stoll Y, Pethran A, Pfaller A, Rommelt H, Fruhmann G. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994; 51: 229-233.
• 5 Favier B, Gilles L, Gesage M, Latour JF. Analysis of cyclophosphamide in the urine of antineoplastic drug handlers. Bull Cancer 2003; 90: 905-909.
• 6 Favier B, Gilles L, Latour JF, Desage M, Giammarile F. Contamination of syringe plungers during the sampling of cyclophosphamide solutions. J Oncol Pharm Pract 2005; 11: 1-5.
• 7 Favier B, Gilles L, Ardiet C, Latour JF. External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J Oncol Pharm Practice 2003; 09: 15-20.
• 8 Goloni-Bertollo EM, Tajara EH, Manzato AJ, Varella-Garcia M. Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int J Cancer 1992; 50: 341-344.
• 9 Grummt T, Grummt H-J, Schott G. Chromosomal aberrations in peripheral lymphocytes of nurses and physicians handling antineoplastic drugs. Mutat Res 1993; 302: 19-24.
• 10 Labuhn K, Valanis B, Schoeny R, Loveday K, Vollmer WM. Nurses’ and pharmacists’ exposure to antineoplastic drugs: Findings from industrial hygiene scans and urine mutagenicity tests. Cancer Nursing 1998; 21: 79-89.
• 11 Lassila O, Toivanen A, Nordman E. Immune function in nurses handling cytostatic drugs. Lancet 1980; 02: 482.
• 12 Lovejoy N, Powers L, Flessel P, Lecocq G, Guirguis G, Chang K. Mutagenicity in urine of hospital workers who prepare and administer chemotherapy agents. EMS Abstracts 1985; 7.
• 13 Niklasson B, Bjorkner B, Hansen L. Occupational contact dermatitis from antitumor agent intermediates. Contact Dermatitis 1990; 22: 233-235.
• 14 Peelen S, Roeleveld N, Heederik D, Krombout H, de Kort W. Toxic effects on reproduction in hospital personnel. Dutch Ministry of Social Affairs and. Employment. 1999
• 15 Sessink PJM, Verplanke AJW, Herber RFM, Bos RP. Occupational exposure to antineoplastic agents and parameters for renal dysfunction. Int Arch Occup Environ Health 1997; 69: 215-218.
• 16 Sessink PJM, Kroese ED, van Kranen HJ, Bos RP. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Inter Arch Occup Environ Health 1993; 67: 317-323.
• 17 Sotaniemi EA, Sutinen S, Arranto AJ, Sutinen S, Sotaniemi KA, Lehtola J, Pelkonen RO. Liver damage in nurses handling cytostatic agents. Acta Med Scand 1983; 214: 181-189.
• 18 Stücker I, Caillard J-F, Collin R, Gout M, Poyen D, Hémon D. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990; 16: 102-107.
• 19 Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs 1993; 16: 288-295.